Olanzapine for the treatment of psychosis in patients with Parkinson’s disease and dementia

Laura Marsh, Constantine Lyketsos, Stephen G. Reich

Research output: Contribution to journalArticlepeer-review

Abstract

Psychotic symptoms are a common complication in Parkinson’s disease with dementia. The authors conducted an open-label 6-week trial of olanzapine preceded by a placebo lead-in in five subjects with Parkinson’s disease, mild to moderately severe dementia, and psychosis. Four of the subjects terminated the trial early because of worsening motor function, sedation, or paranoia. There was no improvement in psychotic symptoms, and functional abilities declined significantly. Olanzapine appears to be poorly tolerated in patients with Parkinson’s disease, psychotic symptoms, and dementia.

Original languageEnglish (US)
Pages (from-to)477-481
Number of pages5
JournalPsychosomatics
Volume42
Issue number6
DOIs
StatePublished - 2001

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Applied Psychology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Olanzapine for the treatment of psychosis in patients with Parkinson’s disease and dementia'. Together they form a unique fingerprint.

Cite this